Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

BiOasis Technologies Inc V.BTI

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  BIOAF

biOasis Technologies Inc is a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue. Its focus is to address unmet medical needs with its proprietary Transcend Platform.
Price: $1.09 | Change: +$0.04 | %Change: +3.81%
Volume: 33,500 | Day High/Low: 1.09/1.05 | 52 Week High/Low: 1.35/0.67
View modes: 
5 stars

hey oilpatch,

any messages? drj  rate and reply
0 stars

RE:RE:RE:RE:Roche

I hear ya, Noobski, but I used "would be" because Transcend needs some more success, and it wouldn't be anything positive for Roche unless they acquired it. So there is still a lot of "would be" in...read more
0 stars

RE:RE:RE:RE:Roche

j.d the way you write is almost as though you've written books?....not sure just the style seems like that....I just wish I could spell half as good....then id be getting somewhere  rate and reply
0 stars

RE:RE:RE:Roche

One adjustment JD, your second paragraph; I think it sounds better if you replace “would be” with “is”  rate and reply
0 stars

BTI Level 2 - 3pm ET

Level 2 Quote Market Maker Shares Bid Price Ask Price Shares Market Maker     9,700 1.070 1.090 21,600     46,400 1.050 1.100 13,000     6,200 1.040 1.110 3,000...read more
5 stars

RE:RE:Roche

The cancers wars continue. Kadcyla (TDM-1) has failed to show increased efficacy. Roche cannot mitigate its loss of patent protection for Herceptin. The big thing about a biOasis Transcend peptide...read more
0 stars

RE:RE:Seeking Alpha

me thinks we're going for a major joy ride very soon!   drj!  rate and reply
0 stars

RE:RE:Roche

I dont understand ....it would be so cheap at this poi t for someone to take a stab at us to possibly advance their therPies to the brain. .....so cheap....and yest we never hear of an offer or a...read more
0 stars

RE:Seeking Alpha

She also discussed BTI in another blog post in July.  Kevetrin The Salt That Is Worth Gold! Jul 16, 2014 2:28 PM About 1/3 the way down in a paragraph starting with "For approximately a year, Roche...read more
0 stars

RE:Roche

i wouldn't be surprised that roche, like others, have had trouble with percentage of injected dose being ablel to cross bbb to show efficacy.   maybe they want to take a closer look at our peptide...read more
0 stars

RE:Roche

Perhaps Roche will be looking for a way to distinguish Herceptin from the Biosimilars? --------------------------------- Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster...read more
0 stars

Roche

Double blow for Roche as breast cancer, Alzheimer's studies fail Fri Dec 19, 2014 12:52pm GMT By Silke Koltrowitz and Ben Hirschler ZURICH/LONDON, Dec 19 (Reuters) - Roche suffered a double blow on...read more
0 stars

RE:RE:Seeking Alpha

You just soumded like smeagull from lord of the rings lol doc  rate and reply
5 stars

RE:Seeking Alpha

2 very important statements in there. 1) Bioasis has failed to define a pathway to and through the US, and or Canadian FDA without having a major partner. 2) I believe that both Cellceutix and Bioasis...read more
0 stars

RE:Seeking Alpha

Thanks for sharing.  rate and reply
0 stars

Seeking Alpha

Interesting read! http://seekingalpha.com/instablog/21116141-ellaruth/3428735-bioasis-positioned-to-be-swallowed-by-astrazenecas-medimmune  rate and reply
0 stars

RE:RE:RE:RE:anyone else think

US investor(s) stepped up today.  OTC volume was 19,500 vs 2,085 average.  Our low dollar helps.  rate and reply
3 stars

RE:RE:RE:anyone else think

Ya, it was that dastardwy Anon..., uh, wait a second here, uh, nope, Anonymous bought the last 8900 shares.  It was that dastardwy Scotia Capital doing all that selling! Hey, how come nobody is...read more
0 stars

RE:RE:anyone else think

refreshing to see someone other than me getting frustrated with how the shareprice behaves  rate and reply
5 stars

RE:anyone else think

that this thing is ready to move? If we ever get past the folks who take advantage of a move up and sell going into the close.  rate and reply